Floatz logo

Thalidomide

Intraocular Melanoma

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

64 Active assets in the Intraocular Melanoma cohort.

Asset / SponsorPhaseRating
Ifa
Craig L Slingluff, Jr
Phase 2BBB
Tyrosinase Peptide
University of Southern California
Phase 3BB
Sargramostim
Thomas Jefferson University
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2/3BB
Darovasertib
IDEAYA Biosciences
Phase 3BB

View all 50 →

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
beta-thalassemia majorDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →